menu
    • menu

    Company profile for Gradalis

    NEW Drugs in Dev: 6
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications including an upcoming Phase 3 registration trial in patients with ovarian cancer. The company’s proprietary bi-shRNA therapy platform, which has been proven in its clinical studies, can be utilized to silence a broad range of genes and is applicable to multiple cancer types.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GradalisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2545 Golden Bear Drive, Suite 110, Carrollton, TX 75006
    Telephone
    Telephone
    (214) 442-8100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gradalisinc.com/about/company
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Solve GNE Advances GNE Myopathy Program Toward Phase 1 Trial
    Solve GNE Advances GNE Myopathy Program Toward Phase 1 Trial

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256342/0/en/Solve-GNE-Highlights-New-Research-Expands-Funding-Efforts-and-Advances-Toward-a-Phase-I-Clinical-Trial-for-GNE-Myopathy.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Gradalis' Vigil Boosts Survival in cTMB-H/HRP Ovarian Cancer
    Gradalis' Vigil Boosts Survival in cTMB-H/HRP Ovarian Cancer

    14 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/14/3219157/31499/en/Gradalis-Vigil-Demonstrates-Significant-Survival-Benefit-in-cTMB-H-HRP-Ovarian-Cancer-Patients-Phase-2b-VITAL-Trial-Analysis-Published-in-JCO-Precision-Oncology.html

    GLOBENEWSWIRE
    14 Jan 2026
    Share Share
    Gradalis Appoints Steven D. Weinstein As Chief Executive Officer
    Gradalis Appoints Steven D. Weinstein As Chief Executive Officer

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216807/31499/en/Gradalis-Appoints-Steven-D-Weinstein-as-Chief-Executive-Officer.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Gradalis Develops Exome Sequencing Pipeline for Tumor Mutation
    Gradalis Develops Exome Sequencing Pipeline for Tumor Mutation

    14 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/14/3042961/31499/en/Gradalis-Announces-Development-of-Clinically-Relevant-Exome-Sequencing-Bioinformatics-Pipeline-to-Determine-Clonal-Tumor-Mutation-Burden.html

    GLOBENEWSWIRE
    14 Mar 2025
    Share Share
    Gradalis Secures FDA RMAT for Vigil Immunotherapy in Ovarian Cancer
    Gradalis Secures FDA RMAT for Vigil Immunotherapy in Ovarian Cancer

    05 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/05/3021053/31499/en/Gradalis-Secures-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-Vigil-Gemogenovatucel-T-An-Investigational-Personalized-Immunotherapy-for-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    05 Feb 2025
    Share Share
    GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on KRAS Mutations
    GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on KRAS Mutations

    04 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/04/2804387/0/en/Gradalis-GRAD1405-bi-shRNAi-Candidate-First-to-Show-Positive-Impact-on-Three-Key-KRAS-Mutations-Identified-in-Drug-Resistant-Lung-Colon-and-Pancreatic-Cancers.html

    GLOBENEWSWIRE
    04 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search